HOME >> BIOLOGY >> NEWS
Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis

1 million Americans with rheumatoid arthritis, said Dr. David Karp, chief of rheumatic diseases and associate director of the Harold C. Simmons Arthritis Research Center.

"This is a very novel approach; one that has not been looked at by other investigators," he said. "This family of proteins is not only implicated in the painful inflammation of rheumatoid arthritis, but also the joint destruction that accompanies the disease. These proteins also may be critical for other autoimmune diseases like multiple sclerosis and systemic lupus erythematosis."

Rheumatoid arthritis is an autoimmune disease in which the body's immune system attacks its own tissues, mistaking them for foreign substances like bacteria or viruses. This disease is characterized by redness, swelling, loss of joint function and deterioration of cartilage and bone in the joints.

There is no cure for the disease, but there are currently three drugs that specifically target TNF inhibition. Although these drugs have been shown to be effective in decreasing the pain associated with the disease and in some cases joint destruction, some patients develop antibodies against the drugs, which may require the administration of higher doses.

"This side effect may lower the effectiveness of these drugs," Dr. Tansey said. "Our prediction is that because these TNF variants are virtually identical to native TNF, the body will not form antibodies against them, but this will have to be tested."

The TNF variants are currently in preclinical development at Xencor.

Anti-TNF therapy may also be useful in blocking inflammation in neurodegenerative diseases like Alzheimer's and Parkinson's disease, Dr. Tansey said.

Dr. Tansey recently received a $200,000 grant from the Michael J. Fox Foundation to examine the role that elevated levels of TNF play in the loss of dopamine-producing neurons, which lead to Parkinson's disease.

Other researchers who contributed to
'"/>

Contact: Amy Shields
amy.shields@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
25-Sep-2003


Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2019)... ... 30, 2019 , ... Join Julie Peacock, Vice President of ... Wednesday, June 19, 2019 at 1pm EDT where she will demonstrate how role-based ... and contract research organizations (CROs) can improve collaboration, auditing, document tracking and reporting. ...
(Date:5/24/2019)... THE WOODLANDS, Texas (PRWEB) , ... May 24, 2019 , ... ... has been published and is now available on the company’s global website. , Crystallography ... focusing on single crystal X-ray diffraction. It serves the X-ray analysis community by presenting ...
(Date:5/22/2019)... ... May 22, 2019 , ... Leak Detection Associates (LDA), the ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce ... Ltd has been signed. The agreement will grant exclusive rights for IPP ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... LA JOLLA, Calif. (PRWEB) , ... May 14, 2019 , ... ... announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet. ... SneakPeek Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to provide ... USA Inc. aims to enhance customer satisfaction through the effective implementation of ...
(Date:4/25/2019)... Calif. (PRWEB) , ... April 23, 2019 , ... Frank is an albino, deaf Great ... did not want him due to his health issues. Despite his hearing impairment, he was ... Tom, and the two would play all day, every day. As the two grew, playtime ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, ... a $2 million bench plant expansion to increase production of methylene malonate monomers ... design and construction of Sirrus’ full-scale production facility, which is scheduled to break ...
Breaking Biology Technology:
Cached News: